Hemophagocytic Lymphohistiocytosis (HLH) Market
The total incident population of Hemophagocytic Lymphohistiocytosis in the seven major markets was 4,435 in 2017. There are 2 types of Hemophagocytic Lymphohistiocytosis: familial and acquired. Familial HLH accounts for about 25% of cases and families pass down the condition.
The market size of Hemophagocytic Lymphohistiocytosis in 2017 in the 7MM was found to be USD 6.1 Million, which is expected to grow during the forecast period 2017-2030.
The key players in the Hemophagocytic Lymphohistiocytosis market include Swedish Orphan Biovitrum (Sobi), AB2 Bio Ltd, and others.
For more detailed information on Hemophagocytic Lymphohistiocytosis Market, visit: https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market
Contact Dermatitis Market
The total diagnosed prevalent population of Contact Dermatitis in the 7MM was 43,359,201 in 2017. With around 13,786,942 cases in 2017 the United States accounted for the highest number of diagnosed prevalent cases among the seven major markets.
In 2017, the market size of Contact Dermatitis was found to be USD 7,831 Million in seven major markets, which is expected to increase during the forecast period 2017-2030.
The key pharma companies in the Contact Dermatitis Market include Edesa Biotech, Hapten Sciences and many others.
For more detailed information on Contact Dermatitis Market, visit: https://www.delveinsight.com/report-store/contact-dermatitis-market
Metabolic Acidosis Market Outlook
In 2017, the total Metabolic acidosis prevalent cases in the 7MM+3EM (the US, EU5 (the UK, Italy, Germany, France, and Spain) and Japan + China, Brazil and Mexico) were 19,982,276.
The Metabolic acidosis market size was estimated to be USD 26.89 Million in 2017 in 7MM+3EM, which is expected to change during the forecast period 2017-2030. The Metabolic Acidosis Market is significantly dominated by alkali therapies.
The key players in the Metabolic Acidosis market includes Tricida, Advicenne Pharma, and others.
For more detailed information on Metabolic Acidosis Market visit:
https://www.delveinsight.com/blog/metabolic-acidosis-market/
Acute Respiratory Distress Syndrome Market
In 2017, the total incident population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM was 7,99,872, out of all the incidence cases in seven major markets, the US accounts for about 4,95,655 cases.
The market size of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is expected to grow at a CAGR of 9.55% during the study period (2017-2030).
The key pharma players in the Acute Respiratory Distress Syndrome (ARDS) market includes Faron Pharmaceuticals, Biomarck Pharmaceuticals, Athersys, Inc, Alexion Pharmaceuticals, Apeptico, and many others.
For more detailed information on Acute Respiratory Distress Syndrome (ARDS) Market, visit:
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
Postpartum Depression Market
It has been observed that approximately 60-80% of all the women who give birth experience Postpartum blues (PPB) also known as ‘baby blues’, and in about 10-15% of the women suffering from postpartum blues, the mild condition of baby blues worsens and advances to Postpartum Depression (PPD).
The total diagnosed Postpartum Depression (PPD) prevalent population in the seven major markets was found to be 1,134,800 in 2017, which is expected to increase further during the study period (2017-2030). The western countries have the highest Postpartum Depression prevalence; while the Asian countries account for a relatively comparable PPD preponderance.
The Market Size of Postpartum Depression in the seven major markets was estimated to be USD 138.75 Million in 2017, with the United states occupying for maximum PPD Market share.
The key players in the Postpartum Depression market include Sage Therapeutics, Marinus Pharmaceuticals and others.
For more information on Postpartum Depression Market visit:
https://www.delveinsight.com/blog/postpartum-depression-market/
COVID-19 Vaccine Candidates In The Pipeline
Coronavirus pandemic has infected over 10 million people worldwide with over half a million casualties. Countries worldwide are now easing the locked down restrictions to bring their economies back on track by allowing essential services and activities. With the ease in restrictions and lockdown measures the probability of spread of virus is expected to increase in the coming days.
The pharmaceutical and biotech companies are working round the clock to develop the effective and safe vaccine for Coronavirus. As of today, more than 150 candidate vaccines are in the preclinical and clinical evaluation phases.
Some of the front-runners in the Covid-19 vaccine developments includes:
Moderna (mRNA-1273)
AstraZeneca/Oxford (ChAdOx1 nCoV-19 /AZD1222)
CanSino Biologics Inc (Ad5-nCoV)
Inovio Pharmaceuticals (INO-4800)
Sinovac Life Sciences (CoronaVac)
The vaccine development rigorous research and testing process, the availability of safe & effective Covid-19 vaccine in the market is likely to take one and half years.
For more detailed information on COVID-19 Vaccine Candidates, visit: https://www.delveinsight.com/blog/coronavirus-vaccine-candidates/
Pemphigus Vulgaris Market
The total diagnosed prevalent cases of Pemphigus Vulgaris in the 7MM was 41,217 in 2017. Among 7MM, the United States accounted for the highest number of diagnosed prevalent cases of PV in 2017, while France had the lowest number of cases.
The market size of Pemphigus Vulgaris in 7MM was found to be USD 181.78 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key pharma companies in the Pemphigus Vulgaris Market include Principia Biopharma, Novartis/ MorphoSys, Argenx, Topas Therapeutics, and many others.
For more detailed information on pV market, visit:
https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
Fragile X Syndrome (FXS) Market
The total cases of Fragile X Syndrome (FXS) in the 7MM was 117,962 in 2017. While in the United States, the diagnosed prevalent cases of FXS in 2017 was found to be 67,654.
The market size of Fragile X Syndrome (FXS) was USD 33.8 Million in 2017 and is expected to increase during the forecast period 2017-2030.
The key pharma companies in the Fragile X Syndrome (FXS) market include Zynerba Pharmaceuticals, Tetra Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, Marinus Pharmaceuticals, Alcobra Pharmaceuticals/ Arcturus Therapeutics and many others.
For more detailed information on Fragile X Syndrome (FXS) market, visit: https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market
Cytokine Release Syndrome Market
The total number of patients who developed Cytokine Release Syndrome in the 7MM were 31 in 2017.
The market size of Cytokine Release Syndrome (CRS) in the seven major markets was found to be USD 0.16 Million in 2017.
The key pharma companies in the Cytokine Release Syndrome (CRS) market includes Novartis, Swedish Orphan Biovitrum (Sobi), Incyte Corporation, Jazz pharmaceuticals, CytoSorbents and many others.
For more detailed information on Cytokine Release Syndrome Market, visit:
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market
Urinary Incontinence Market
Urinary incontinence , which is also known as the loss of bladder control is a common problem in which a person leaks urine by chance. Although, it may happen to anyone but older people especially women are severely affected by this problem. Urinary incontinence is not just a health problem, it can affect emotional, psychological and social life.
According to the research study of Minassian et al., The prevalence of urgency UI and mixed UI is low between 20 and 30 years of age, but gradually increases with age, with an average prevalence of 5% and 11%, respectively.
The Key Pharmaceutical Companies in the Urinary Incontinence market include:
Velicept Therapeutics
Urovant Sciences
IXALTIS
Cook MyoSite
Taiho Pharmaceutical
ALZA Corporation
Pfizer
Astellas Pharma
and many others
For more detailed information on Urinary Incontinence Market, visit:
https://www.delveinsight.com/report-store/urinary-incontinence-market
Gorlin Syndrome Market
Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-–Goltz syndrome, is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows the high level of penetrance and variable expressiveness.
It has also been observed that the estimated prevalence of NBCCS has no observed sex predilection i.e., the male-to-female ratio is 1:1.
As per the study conducted by M. Lorenzo et al., “the estimated prevalence of Gorlin Syndrome varies from 1/57,000 to 1/256,000”.
The pharmaceutical companies in the Gorlin Syndrome market includes:
HedgePath Pharmaceuticals
Mayne Pharma
PellePharm
Leo-Pharma
Phyton Biotech
And many others
For more detailed information on Gorlin Syndrome Market, visit:
https://www.delveinsight.com/report-store/gorlin-syndrome-market
Chronic pancreatitis is the progressive disorder associated with the destruction of the pancreas. The most common symptoms are upper abdominal pain and diarrhea. As the disease becomes more chronic, patients can develop malnutrition and weight loss.
Prevalence estimates for CP are limited to only a few populations. The overall prevalence of CP shows high variability. In recent studies the prevalence ranges around 40-50 per 100,000 population.
Non-alcoholic etiologies are identified more frequently among women, and can account for up to 70% of cases.
Hospitalization in patients with CP could be due to AP flares, pain, maldigestion, and local complications. More than 90% of patients are hospitalized on at least one occasion in their lifetime for pain related to CP.
Chronic Pancreatitis is found to be more common in men than women.
Key Pharma Companies in the Chronic Pancreatitis market includes:
Kangen Pharmaceuticals
AzurRxBioPharma
Theraly Fibrosis
Aptalis Pharma
EURAND Pharmaceuticals
And many others
For more detailed information on Chronic Pancreatitis Market, visit: https://www.delveinsight.com/report-store/chronic-pancreatitis-market
Blastic Plasmacytoid Dendritic Cell Neoplasm Market
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions.
Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients.
More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients aged 60 years and older.
According to the Leukemia and Lymphoma Society, BPDCN constitutes less than 1% of all hematologic malignancies, resulting in an estimated 1,000 to 1,400 cases occurring annually in the US and Europe combined.
90% of patients with BPDCN present with asymptomatic skin lesions – and early recognition can be challenging due to overlapping features with other benign and malignant disorders.
The key pharmaceutical Companies in the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market includes:
Immunogen
MustangBio
Abbvie
Stemline Therapeutics
Cellectis
Xencor
and many others
For more detailed information on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market, visit:
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market
Vernal Keratoconjunctivitis Market Analysis
In 2017, the total prevalent population of Vernal Keratoconjunctivitis in the major markets (which includes the USA, Germany, France, the UK, Italy, Spain, Japan, China, Egypt, Saudi Arabia, and Russia) was found to be 4,752,356 and is expected to increase during the forecast period 2017-2030.
The market size of Vernal Keratoconjunctivitis in the major markets (i.e. 7MM, China, Egypt, Saudi Arabia, and Russia) was USD 307.89 Million in 2017.
The key factors such as rise in prevalence, disease awareness & diagnosis, and research & development are expected to drive the VKC market forward in the coming years.
The key players in the Vernal Keratoconjunctivitis market include Allakos Inc., iCo Therapeutics, Akari Therapeutics, Santen, Novartis, Alcon, Senju Pharmaceutical, and many others.
For more detailed information on Vernal Keratoconjunctivitis market, visit: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
Nontuberculous Mycobacterial Infection Market Analysis
As per the Delveinsight, total Nontuberculous mycobacterial (NTM) infection prevalence in the 7MM (the United States, EU5 (the United Kingdom, Germany, France, Italy and Spain), and Japan) is expected to increase with a CAGR of 0.6% by 2030.
The Nontuberculous mycobacterial infection prevalence in the United States is the highest among the seven major markets, followed by Japan. While in the European-5 countries, Germany accounted for the highest NTM infection prevalent population followed by France and the UK, with Spain accounting for the lowest NTM infection prevalent population.
The Nontuberculous Mycobacterial Infection Market in the seven major markets is expected to increase at a CAGR of 6.6% for the study period i.e. 2017–2030.
The Nontuberculous Mycobacterial Infection Market Drivers-
Increasing demand of therapeutic products
Impending opportunities in the market
Increasing prevalence, and
Increasing spending on branded drugs
The key companies in the Nontuberculous mycobacterial (NTM) infection Market include Insmed Incorporated, RedHill Biopharma Ltd., Novoteris, Savara Inc., Beyond Air™ and others.
For more detailed information on Nontuberculous Mycobacterial (NTM) Infection market, visit: https://www.delveinsight.com/blog/nontuberculous-mycobacterial-infection-market-size/
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
In the 7MM, the total prevalent population of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder was estimated to be 16,397 cases in 2017.
The market size of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in the seven major markets was found to be USD 5.95 Million in 2017 and is expected to grow during the study period (2017–2030).
The key pharma companies in the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market includes Marinus Pharmaceuticals, Ovid Therapeutics/Takeda, Zogenix, PTC Therapeutics, and many others.
For more detailed information on Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market, visit: https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Sciatica Market
The total prevalent population of Sciatica in the seven major markets was 27,022,660 in 2017.
In 2017, the market size of Sciatica in the 7MM was found to be USD 2,047.28 Million and is expected to grow during the study period (2017–2030).
Factors such as survival rate, improved awareness, efficient pipeline activity, increased research and development are expected to drive the Sciatica market forward in the coming years.
The key players in the Sciatica market includes Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kolon Life Science, Teijin America, and many others.
For more detailed information on Sciatica Market, visit: https://www.delveinsight.com/report-store/sciatica-market
Small Cell Lung Cancer Market Analysis
Small cell lung cancer can affect all the age groups; however, middle-aged and older adults are observed to be affected more as compared to other age groups. A gender gap can also be witnessed with a higher male Small Cell Lung Cancer incidence than females in the seven major markets.
As per DelveInsight, approximately 55% of the Small Cell Lung Cancer diagnosed pool consisted of males; however, during the last few years, the incidence gap has started to get narrower. The trend can be attributable to the rise in smoking, which is a significant risk factor of Small cell lung cancer
According to Delveinsight, around 25% of all the cases were of limited-stage whereas Extensive-stage SCLC constitutes the remaining 75% of the cases, in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain), and Japan) in 2017.
The total Small-cell lung cancer incident cases are expected to increase with a CAGR of 1.7% for the study period 2017-30. Among the seven major markets, the US accounted for the highest Small Cell Lung Cancer incidence.
As per DelveInsight, the Small cell lung cancer market size is expected to grow at a CAGR of 15.2% during the study period (2017–30).
Rising prevalence, rich pipeline, healthcare spending, improved R&D, and discovery of novel targets, and approval of immune checkpoint inhibitors are some of the key factors expected to drive the Small Cell Lung Cancer Market in the upcoming years.
The key players in the Small Cell Lung Cancer Market includes:
Bristol-Myers Squibb
Merck
AstraZeneca
Genentech
G1 Therapeutics
PharmaMar
United Therapeutics
EpicentRx
Amgen
Fate Therapeutics
And many others.
For more information on Small Cell Lung Cancer Market, visit:
https://www.delveinsight.com/blog/small-cell-lung-cancer-market/
Most Common Cancers In Men And Women
The five common cancers, in terms of number of deaths and cases worldwide includes-
Lung Cancer
With over 2 million cases and 1.76 million deaths, lung cancer accounts for the highest number of diagnosed and cancer-related death cases worldwide. Cigarette smoking is the major risk factor for lung cancer. The risk for Lung cancer increases with the quality and duration of smoking.
Colorectal Cancer
Colorectal cancer, also called bowel cancer, colon cancer, or rectal cancer starts in the colon or the rectum. As per WHO, “around 1.80 million cases and 862,000 deaths occur due to Colorectal cancer worldwide in 2018“.
Skin Cancer
In some countries like the USA, a very large number of skin cancers are registered every year. The various forms of skin cancer are divided into two main types namely Non-melanoma skin cancer and Melanoma skin cancer. According to the American Academy of Dermatology Association estimation “around 1 in 5 Americans will develop skin cancer in their lifetime & approximately 9,500 people in the united states are diagnosed with skin cancer every day”.
Breast Cancer
Breast Cancer is the most prevalent cancer in women. Globally, around 2 Million women are affected with it each year, and also causes the highest number of cancer-related deaths among womens. According to WHO, “In 2018, an estimated 627,000 women died due to Breast Cancer, which is almost 15% of all death due to cancer in women.
Prostate Cancer
Prostate Cancer is the most common cancer in men. Around 1.28 million cases of prostate cancer have been registered in 2018, worldwide.
Over the past few years the survival rate of cancer is increasing. The research and development in the field of medicine is expected to further increase the survival rate. The new techniques such as Precision medicine and immunotherapies in the field of cancer treatment is expected to make a significant impact in cancer treatment in the coming years.
For more detailed information on Most Common Cancers, visit:
https://www.delveinsight.com/blog/most-common-cancers-2/
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market
The total cases of Programmed Death-Ligand 1 (PD-L1) mutated Non-small Cell Lung Cancer (NSCLC) in the 7MM were observed to be 242,014 in 2017.
The therapeutic market size of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in seven major markets was found to be USD 6,536 million in 2017 which is expected to increase during the study period (2017–2030).
The key players in the PD-L1 NSCLC Market include Pfizer/Merck, Regeneron Pharmaceuticals, Novartis, GlaxoSmithKline and others.
For more detailed information on PD-L1 NSCLC Market, visit:
https://www.delveinsight.com/report-store/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market
Joined Feb 2020
